The Generalized Seizures drugs in development market research report provides comprehensive information on the therapeutics under development for Generalized Seizures, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Generalized Seizures. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Generalized Seizures and features dormant and discontinued products.
GlobalData tracks 16 drugs in development for Generalized Seizures by 14 companies/universities/institutes. The top development phase for Generalized Seizures is preclinical with six drugs in that stage. The Generalized Seizures pipeline has 14 drugs in development by companies and two by universities/ institutes. Some of the companies in the Generalized Seizures pipeline products market are: Taysha Gene Therapies, UCB and Ionis Pharmaceuticals.
The key targets in the Generalized Seizures pipeline products market include Voltage Gated Sodium Channel (SCN), Potassium Voltage Gated Channel Subfamily KQT Member 3, and Potassium Voltage Gated Channel Subfamily KQT Member 2.
The key mechanisms of action in the Generalized Seizures pipeline product include Potassium Voltage Gated Channel Subfamily KQT Member 2 Activator with two drugs in Phase III. The Generalized Seizures pipeline products include four routes of administration with the top ROA being Oral and five key molecule types in the Generalized Seizures pipeline products market including Small Molecule, and Gene Therapy.
Generalized Seizures overview
Generalized seizures, are a type of seizure that impairs consciousness and distorts the electrical activity of the whole or a larger portion of the brain. It occurs when the abnormal electrical activity causing a seizure begins in both halves (hemispheres) of the brain at the same time. Generalized seizures occur in various seizure syndromes, including myoclonic epilepsy, familial neonatal convulsions, childhood absence epilepsy, absence epilepsy, infantile spasms (West’s syndrome), Juvenile Myoclonic Epilepsy, Lennox-Gastaut syndrome and Generalized epilepsy with occipital semiology. Generalized seizures can be either absence seizures, myoclonic seizures, clonic seizures, tonic-clonic seizures or atonic seizures.
For a complete picture of Generalized Seizures’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
